Biotec Pharmacon presents on 17 August at 08:30 its interim report for the
second quarter of 2017
Speaker at the presentation will be CEO Svein W. F. Lien, MD ArcticZymes Jethro
Holter and Vice President Marketing Stuart Devine.
Please find the Q2 2017 report and presentation attached. The presentation is
also available as a webcast with log-on at www.biotec.no. It will be possible to
submit questions to the speaker from the webcast console
For further information:
Svein Lien, CEO, +47 922 89 323, svein.lien@biotec.no
Børge Sørvoll, CFO, +47 952 90 187 borge.sorvoll@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, an advanced wound care product
for stalled wounds with a proprietary medicinal ingredient. ArcticZymes
develops, produces and markets recombinant enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth markets where
rapid technological developments are creating a strong demand for new and
improved enzymes.